Enanta Pharmaceuticals (ENTA) stock price is $11.67, up 2.28% on the day, as of Oct 20, 2026. It has a market cap of $338.32Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap338.32 Mn
P/E-5.35
P/S5.18
Div. Yield0.00
Revenue Growth (1y) (Qtr)-21.60
Add ratio to table…
About
Enanta Pharmaceuticals Inc is a biotechnology company that concentrates on the discovery and development of small molecule therapeutics for virology and immunology indications. The firm applies a chemistry driven strategy to generate compounds that either block viral replication or modulate key immune signaling pathways. Its research portfolio includes programs aimed at respiratory syncytial virus SARS CoV 2 hepatitis B virus and several type 2 inflammatory diseases such as…
Enanta Pharmaceuticals Inc is a biotechnology company that concentrates on the discovery and development of small molecule therapeutics for virology and immunology indications. The firm applies a chemistry driven strategy to generate compounds that either block viral replication or modulate key immune signaling pathways. Its research portfolio includes programs aimed at respiratory syncytial virus SARS CoV 2 hepatitis B virus and several type 2 inflammatory diseases such as chronic spontaneous urticaria and atopic dermatitis. The company advances its candidates through preclinical studies and clinical trials while actively seeking collaboration out licensing or partnership opportunities that can accelerate development. Enanta Pharmaceuticals Inc also derives income from royalty payments tied to its earlier hepatitis C virus collaboration with AbbVie. The organization maintains a lean operational structure that emphasizes internal scientific expertise and disciplined capital allocation to support its pipeline.
Enanta Pharmaceuticals Inc generates revenue mainly from royalty streams received under its agreement with AbbVie for the hepatitis C virus regimen MAVYRET MAVIRET. Under this arrangement the company receives tiered double digit royalties on net sales of the glecaprevir pibrentasvir combination which are paid quarterly based on sales thresholds. In addition to royalties Enanta Pharmaceuticals Inc may obtain milestone payments upfront fees and additional royalties from licensing or partnership deals for its proprietary assets in respiratory syncytial virus SARS CoV 2 hepatitis B virus and immunology programs. The firm periodically accesses the public equity markets to raise capital for research and development and may also pursue non dilutive financing mechanisms such as grants or debt facilities when appropriate. Revenue is therefore composed of recurring royalty income occasional partnership proceeds and periodic equity financing activities. The company’s financial strategy seeks to balance these sources to fund ongoing preclinical and clinical work while preserving flexibility for future business development initiatives.
Enanta Pharmaceuticals Inc operates through the following segments: Virology and Immunology.
The Virology segment comprises the company’s efforts to discover and develop small molecule antiviral drugs that target viral replication steps. Activities within this segment include the identification and optimization of inhibitors of the respiratory syncytial virus N protein and L protein as well as compounds aimed at SARS CoV 2 and hepatitis B virus. The segment supports preclinical chemistry medicinal chemistry and virology assays to evaluate potency selectivity and pharmacokinetic profiles. Clinical work in this segment involves phase 1 and phase 2 studies to assess safety tolerability and antiviral effect in healthy volunteers and patient populations. The Virology segment also explores partnership opportunities to advance promising candidates into later stage trials and potential commercialization.
The Immunology segment focuses on designing oral small molecule inhibitors that modulate key immune mediators such as KIT and STAT6 to treat type 2 inflammatory diseases. Work in this segment includes the identification of compounds that can deplete mast cells through KIT inhibition or block IL 4 IL 13 signaling through STAT6 inhibition. The segment conducts biochemical cellular and animal model studies to validate target engagement and downstream effects on cytokine production. Preclinical pharmacology and toxicology studies are performed to support investigational new drug filings. Clinical efforts in this segment involve early phase studies in diseases such as chronic spontaneous urticaria atopic dermatitis asthma and related conditions. The Immunology segment also evaluates combination approaches and seeks collaborations that could enhance the therapeutic profile of its candidates.
Enanta Pharmaceuticals Inc occupies a specialized niche in the biotechnology sector where its strength lies in internal chemistry driven drug discovery rather than large scale manufacturing or commercial infrastructure. In the antiviral arena the company faces competition from established pharmaceutical giants such as Gilead Sciences Pfizer Merck and Johnson Johnson as well as focused biotechs like Ark Biosciences Shionogi and Altimmune that are pursuing respiratory syncytial virus therapeutics. These competitors often possess greater financial resources larger clinical development teams and established sales and marketing networks. In the immunology field Enanta Pharmaceuticals Inc contends with players such as Amgen Genentech Roche and newer entrants that are developing oral immunomodulators targeting similar pathways. The firm distinguishes itself by concentrating on replication inhibitors for respiratory syncytial virus which may present a higher barrier to viral resistance compared to entry blockers and by pursuing highly selective kinase and transcription factor inhibitors that aim to achieve a favorable safety and dosing profile. Additionally the royalty income derived from the AbbVie hepatitis C collaboration provides a relatively stable financial foundation that many pure play biotechs lack allowing the company to sustain research efforts through multiple funding cycles.
Enanta Pharmaceuticals Inc serves a diverse set of stakeholders that includes pharmaceutical partners healthcare providers patients and the broader investment community. The company’s current revenue stream originates from AbbVie under the hepatitis C virus collaboration agreement which supplies quarterly royalty payments based on sales of the MAVYRET MAVIRET regimen. Its pipeline candidates are intended for eventual use by hospitals clinics and physicians who treat patients suffering from respiratory syncytial virus SARS CoV 2 hepatitis B virus and inflammatory skin and respiratory conditions. While the filing does not disclose the names of specific end users or commercial partners the company routinely engages with contract research organizations academic medical centers and other biopharma entities to conduct preclinical and clinical studies. These collaborative relationships are essential for advancing candidates through development milestones and for gathering the data necessary to support regulatory submissions. Enanta Pharmaceuticals Inc also interacts with investors analysts and shareholders through public filings presentations and conference calls to communicate progress and outlook.
Sector:HealthcareSector rationaleEnanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule therapeutics for virology and immunology indications, such as RSV and hepatitis B. Its revenue is derived from royalty payments for the hepatitis C drug MAVYRET/MAVIRET and potential milestone payments from licensing its proprietary medical assets.Industry:BiotechnologyBiotechnologyPrimaryEnanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule therapeutics for virology and immunology, specifically targeting RSV, SARS-CoV-2, and hepatitis B. Its revenue model includes royalty payments from its collaboration with AbbVie for the hepatitis C regimen MAVYRET/MAVIRET, as well as potential milestone payments from its proprietary pipeline.Classified using BQ-MICSCIK: 0001177648
Bull & bear
Investment Thesis
▲ Bull case
Enanta Pharmaceuticals is advancing a differentiated RSV pipeline with zelicapavir and EDP-323, both holding Fast Track designation from the FDA, and has demonstrated clinically meaningful benefits in Phase 2 trials, including a week-long improvement in symptom resolution and reduced hospitalization rates in high-risk adults, with new data confirming a high barrier to antiviral resistance from pediatric studies. The company is on track to align with the FDA on an adult Phase 3 study design for zelicapavir later in 2026, which could unlock significant value given the substantial unmet need in RSV therapeutics, particularly for vulnerable populations where current options are limited to supportive care or moderately effective monoclonal antibodies with dosing and accessibility challenges. This progression positions Enanta to potentially capture a meaningful share of a multi-billion dollar RSV market, especially if zelicapavir demonstrates best-in-class oral convenience and efficacy, reducing reliance on inpatient care and offering a scalable outpatient solution that could disrupt the current treatment paradigm and drive rapid adoption among physicians and payers seeking cost-effective, high-impact interventions.
Enanta’s immunology pipeline is building critical momentum with three distinct oral programs targeting the type 2 immune pathway—KIT (EDP-978), STAT6 (EPS-3903), and MRGPRX2—each addressing large, underserved indications like chronic urticaria and asthma, with EDP-978 already in Phase 1 clinical trials and preclinical data showing potent target engagement, favorable pharmacokinetics, and once-daily dosing potential, while EPS-3903 has demonstrated strong preclinical selectivity, lung-specific distribution, and low drug-drug interaction risk across multiple disease models, reducing concerns about safety and tolerability that often plague immunomodulators. The company’s plan to file an IND for EPS-3903 in the second half of 2026 and nominate an MRGPRX2 development candidate in the same period reflects a disciplined, staged expansion of its immunology franchise, leveraging its chemistry-driven discovery engine to build a portfolio of best-in-class oral therapies that could replace injectable biologics for millions of patients, offering superior convenience, lower systemic exposure, and potential cost savings—factors that are increasingly critical in value-based care environments and could support premium pricing and broad payer acceptance upon approval.
Despite ongoing royalty obligations to OMERS, Enanta retains a meaningful economic interest in its HCV royalties, with the structure designed to revert 100% of cash flows to the company after a cap of 1.42 times the $200 million upfront payment is reached—a threshold projected to be surpassed well before the 2032 maturity date given steady AbbVie sales of MAVYRET/MAVIRET, providing a durable, non-dilutive funding stream that supports R&D without eroding equity value. Combined with a cash position of $227.0 million as of March 31, 2026 and management’s assertion of runway into fiscal 2029, this financial foundation allows Enanta to advance multiple late-stage candidates simultaneously without urgent need for dilutive financing, preserving upside potential for shareholders as milestones like Phase 3 initiation for zelicapavir and IND filings for immunology programs unfold in 2026, which could trigger re-rating of the stock based on de-risked pipeline progress and near-term inflection points rather than distant, speculative outcomes.
Enanta Pharmaceuticals is advancing a differentiated RSV pipeline with zelicapavir and EDP-323, both holding Fast Track designation from the FDA, and has demonstrated clinically meaningful benefits in Phase 2 trials, including a week-long improvement in symptom resolution and reduced hospitalization rates in high-risk adults, with new data confirming a high barrier to antiviral resistance from pediatric studies. The company is on track to align with the FDA on an adult Phase 3 study design for zelicapavir later in 2026, which could unlock significant value given the substantial unmet need in RSV therapeutics, particularly for vulnerable populations where current options are limited to supportive care or moderately effective monoclonal antibodies with dosing and accessibility challenges. This progression positions Enanta to potentially capture a meaningful share of a multi-billion dollar RSV market, especially if zelicapavir demonstrates best-in-class oral convenience and efficacy, reducing reliance on inpatient care and offering a scalable outpatient solution that could disrupt the current treatment paradigm and drive rapid adoption among physicians and payers seeking cost-effective, high-impact interventions.
Enanta’s immunology pipeline is building critical momentum with three distinct oral programs targeting the type 2 immune pathway—KIT (EDP-978), STAT6 (EPS-3903), and MRGPRX2—each addressing large, underserved indications like chronic urticaria and asthma, with EDP-978 already in Phase 1 clinical trials and preclinical data showing potent target engagement, favorable pharmacokinetics, and once-daily dosing potential, while EPS-3903 has demonstrated strong preclinical selectivity, lung-specific distribution, and low drug-drug interaction risk across multiple disease models, reducing concerns about safety and tolerability that often plague immunomodulators. The company’s plan to file an IND for EPS-3903 in the second half of 2026 and nominate an MRGPRX2 development candidate in the same period reflects a disciplined, staged expansion of its immunology franchise, leveraging its chemistry-driven discovery engine to build a portfolio of best-in-class oral therapies that could replace injectable biologics for millions of patients, offering superior convenience, lower systemic exposure, and potential cost savings—factors that are increasingly critical in value-based care environments and could support premium pricing and broad payer acceptance upon approval.
Despite ongoing royalty obligations to OMERS, Enanta retains a meaningful economic interest in its HCV royalties, with the structure designed to revert 100% of cash flows to the company after a cap of 1.42 times the $200 million upfront payment is reached—a threshold projected to be surpassed well before the 2032 maturity date given steady AbbVie sales of MAVYRET/MAVIRET, providing a durable, non-dilutive funding stream that supports R&D without eroding equity value. Combined with a cash position of $227.0 million as of March 31, 2026 and management’s assertion of runway into fiscal 2029, this financial foundation allows Enanta to advance multiple late-stage candidates simultaneously without urgent need for dilutive financing, preserving upside potential for shareholders as milestones like Phase 3 initiation for zelicapavir and IND filings for immunology programs unfold in 2026, which could trigger re-rating of the stock based on de-risked pipeline progress and near-term inflection points rather than distant, speculative outcomes.
Enanta’s reliance on AbbVie’s HCV royalty stream creates a fundamental vulnerability, as MAVYRET/MAVIRET faces accelerating erosion from pan-genotypic competitors and potential generic entry post-patent expiry, with AbbVie’s own guidance indicating declining HCV franchise revenues over the next several years, which would directly compress Enanta’s royalty income and shorten its cash runway despite current assertions of sufficiency into fiscal 2029, particularly if sales decline faster than anticipated due to market share loss or pricing pressure, forcing the company to seek dilutive financing earlier than planned to fund its costly RSV and immunology programs, thereby undermining the very balance sheet strength cited as a key strength in its outlook.
The company’s immunology pipeline, while promising in preclinical models, lacks clinical proof of concept in humans for any of its three oral candidates—KIT, STAT6, or MRGPRX2 inhibitors—with EDP-978 only recently initiating Phase 1 trials and no data yet available on efficacy or safety in patients, meaning that the entire immunology value proposition rests on extrapolation from rodent models and in vitro assays, which have historically failed to translate in immunomodulation due to complex human immune redundancy and off-target effects, raising significant doubt about whether these candidates will achieve the potent, selective, and safe profiles needed to displace established biologics like dupilumab or omalizumab in asthma or chronic urticaria, especially given the high bar for oral small molecules in immune-mediated diseases where biologics have demonstrated transformative efficacy and long-term safety.
Zelicapavir’s Phase 2b data, while showing a modest improvement in symptom duration and hospitalization, does not yet demonstrate a clinically transformative effect size sufficient to guarantee Phase 3 success or regulatory approval, particularly as the trial did not meet its primary endpoint of viral load reduction at all timepoints, and the observed benefits—though statistically significant—may not be deemed meaningful enough by the FDA or payers to justify a new drug application over existing or emerging alternatives, including maternal immunization strategies, long-acting monoclonal antibodies, or other antivirals in development, leaving Enanta vulnerable to a clinical hold, FDA requests for additional data, or a negative Phase 3 outcome that could derail its entire virology franchise and leave the company with limited near-term revenue prospects beyond fading HCV royalties.
Enanta’s reliance on AbbVie’s HCV royalty stream creates a fundamental vulnerability, as MAVYRET/MAVIRET faces accelerating erosion from pan-genotypic competitors and potential generic entry post-patent expiry, with AbbVie’s own guidance indicating declining HCV franchise revenues over the next several years, which would directly compress Enanta’s royalty income and shorten its cash runway despite current assertions of sufficiency into fiscal 2029, particularly if sales decline faster than anticipated due to market share loss or pricing pressure, forcing the company to seek dilutive financing earlier than planned to fund its costly RSV and immunology programs, thereby undermining the very balance sheet strength cited as a key strength in its outlook.
The company’s immunology pipeline, while promising in preclinical models, lacks clinical proof of concept in humans for any of its three oral candidates—KIT, STAT6, or MRGPRX2 inhibitors—with EDP-978 only recently initiating Phase 1 trials and no data yet available on efficacy or safety in patients, meaning that the entire immunology value proposition rests on extrapolation from rodent models and in vitro assays, which have historically failed to translate in immunomodulation due to complex human immune redundancy and off-target effects, raising significant doubt about whether these candidates will achieve the potent, selective, and safe profiles needed to displace established biologics like dupilumab or omalizumab in asthma or chronic urticaria, especially given the high bar for oral small molecules in immune-mediated diseases where biologics have demonstrated transformative efficacy and long-term safety.
Zelicapavir’s Phase 2b data, while showing a modest improvement in symptom duration and hospitalization, does not yet demonstrate a clinically transformative effect size sufficient to guarantee Phase 3 success or regulatory approval, particularly as the trial did not meet its primary endpoint of viral load reduction at all timepoints, and the observed benefits—though statistically significant—may not be deemed meaningful enough by the FDA or payers to justify a new drug application over existing or emerging alternatives, including maternal immunization strategies, long-acting monoclonal antibodies, or other antivirals in development, leaving Enanta vulnerable to a clinical hold, FDA requests for additional data, or a negative Phase 3 outcome that could derail its entire virology franchise and leave the company with limited near-term revenue prospects beyond fading HCV royalties.